AI-generated summary
Naegleria fowleri is a rare but usually fatal parasite that lives in warm freshwater and can enter the brain through the nose. Yucatán is a tourist area in Mexico with both artificial and natural water bodies such as cenotes.
Authorities in the state of Yucatán have closed six man-made lakes following the death of a man in Mexico from a rare infection with the so-called brain-eating amoeba. Protozoa of the genus Naegleria, which also includes the highly dangerous parasite Naegleria fowleri, were detected in six of nine waters examined in the city of Mérida, Yucatán's Health Minister Alberto Alcocer announced.
A 34-year-old man died in September from a brain infection caused by Naegleria fowleri. He had worked as a water ski instructor at an artificial lake in which the pathogen was detected. All six affected bodies of water are used for recreational activities.
Yucatán is located on the peninsula of the same name in southeastern Mexico and is also a popular travel destination for German tourists. Attractions include the Mayan ruins of Chichén Itzá and the natural freshwater pools known as cenotes. The current safety measures concern artificial lakes in Mérida - a general closure of natural bathing waters has not been announced.
Parasite in warm waters: via nose to brain
Infections with the Naegleria fowleri parasite are extremely rare, but are almost always fatal. According to the Robert Koch Institute, the organism is particularly widespread in the subtropics and tropics. The parasite spreads primarily in warm waters and can enter a person's brain through their nose while swimming. There it can cause meningitis, which in most cases leads to coma and ultimately death.
AI outlook — possibilities, not facts
Authorities will take further water samples in Mérida and surrounding areas to monitor the spread of the parasite.
Likely · Within weeks

The European Medicines Agency (EMA) recommends approval of daraxonrasib (trade name Rasonque) for patients with metastatic pancreatic cancer who have failed prior treatment. Studies show significantly longer survival times.

The EMA recommends EU approval of the drug daraxonrasib (trade name Rasonque) for patients with metastatic pancreatic cancer. The drug from the manufacturer Revolution Medicines is intended to significantly extend survival time in patients with previous treatment.

The Federal Joint Committee lowers the age limit for mammography screening from 50 to 45 years. This means that around 2.5 million additional women will be entitled to early detection examinations. The new regulation is expected to come into force on August 1, 2027.

The Bundestag has passed a comprehensive reform of emergency care. Through better interlinking of the numbers 116117 and 112 as well as the introduction of integrated emergency centers, patients should be directed more efficiently to the appropriate level of care.

The average additional contribution rate for statutory health insurance companies will remain at 2.9 percent in 2027. Despite this stability, costs rise for high earners due to a higher contribution assessment limit, while those with private insurance expect premium increases.

The GKV estimators expect a stable average additional contribution of 2.9 percent for 2027. However, experts warn of short-term effects and call for far-reaching structural reforms to avoid impending deficits by 2035.